Skip to content
10-Q

Quarterly Report

Orchestra BioMed Holdings, Inc. OBIO

0001558370-25-007373

← back to feed
Filed
May 12, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 8, 2025 38.31M sh
Long Term Debt Q1 2025 · Mar 31, 2025 $15M
Cash And Equivalents Q1 2025 · Mar 31, 2025 $18.35M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $22.26M
Current Liabilities Q1 2025 · Mar 31, 2025 $15.49M
Current Liabilities Q1 2025 · Dec 31, 2024 $16.21M
Total Liabilities Q1 2025 · Mar 31, 2025 $42.19M
Total Liabilities Q1 2025 · Dec 31, 2024 $43.22M
Current Assets Q1 2025 · Mar 31, 2025 $51.9M
Current Assets Q1 2025 · Dec 31, 2024 $69.17M
Total Assets Q1 2025 · Mar 31, 2025 $59.05M
Total Assets Q1 2025 · Dec 31, 2024 $76.17M
Shares Diluted Q1 2025 · Mar 31, 2024 35.78M sh
Capex Q1 2025 · Mar 31, 2024 $8K
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$13.11M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.38
Eps Basic Q1 2025 · Mar 31, 2024 −$0.38
Sga Expense Q1 2025 · Mar 31, 2024 $5.9M
Rd Expense Q1 2025 · Mar 31, 2024 $9.11M
Net Income Q1 2025 · Mar 31, 2024 −$13.46M
Operating Income Q1 2025 · Mar 31, 2024 −$14.42M
Cost Of Revenue Q1 2025 · Mar 31, 2024 $34K
Revenue Q1 2025 · Mar 31, 2024 $620K